Bcl-2 has been found to be upregulated in a series of tumor types including squamous cell carcinomas of the lung and the potential of Bcl-2 to predict survival for NSCLC patients has been assessed by immunohistochemistry, with different studies demonstrating varying degrees of correlation between Bcl-2 expression and outcome [19-28]. This evidence concerns the gene BCL2 and non-small cell lung carcinoma.